DVA Q2 2026 Earnings Call Summary

DaVita (DVA) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Adjusted Operating Income: $579 million
Adjusted Earnings Per Share (EPS): $4.02
Free Cash Flow: $256 million
Treatment Volume Growth: Increased by 56 basis points year-over-year, slightly exceeding expectations.
Revenue Per Treatment (RPT): Decreased by approximately $2 sequentially, primarily due to lower commercial mix and phosphate binder revenue.
Patient Care Cost (PCC) per Treatment: Declined by approximately $3 sequentially, but year-to-date PCCs have grown over 3% compared to the first half of 2025.
Leverage Ratio: 3.37x consolidated EBITDA, within the target range of 3 to 3.5x.

2. Strategic Updates and Business Highlights

Successful transition of phosphate binders into the Medicare dialysis bundle, improving patient access to effective therapies.
Continued focus on innovation in dialysis, particularly middle molecule clearance through expanded hemodialysis (HD) and hemodiafiltration (HDF).
The MOTheR clinical trial results support the efficacy of expanded HD, which is expected to be deployed broadly across DaVita's network.
A minority investment of $200 million in Elara Caring aims to enhance home health services for dialysis patients.
Share repurchases totaled 2.2 million shares in Q2, maintaining ownership levels with Berkshire Hathaway.

3. Forward Guidance and Outlook

Reaffirmation of full-year 2026 guidance with a midpoint of $2.2 billion for adjusted operating income and $14.65 for adjusted EPS.
Anticipation of treatment volume growth near the top end of the previous guidance range (25-50 basis points).
Expected sequential increase in adjusted operating income of $50 million to $100 million from Q3 to Q4, driven by the IKC business.

4. Bad News, Challenges, or Points of Concern

Decline in revenue per treatment due to lower commercial mix from declining ACA enrollment and reduced phosphate binder revenue.
Patient care costs are growing faster than anticipated, with year-to-date growth exceeding 3%.
Missed treatments were elevated, and fewer admits from closed Fresenius clinics contributed to volume challenges.
The proposed Medicare payment update for 2027 is expected to be below industry cost trends, raising concerns about reimbursement adequacy.

5. Notable Q&A Insights

Management emphasized that treatment volume growth is primarily driven by improved clinical outcomes and mortality rates, rather than new patient starts.
The impact of the new expanded HD technology on economics will be minimal until mortality benefits are realized, expected to start in 2028.
The company is cautious about the competitive landscape, noting that while they are gaining share through clinical performance, the overall industry volume trends are uncertain.
Future growth in the IKC business is anticipated, driven by improved care management and potential new contracts, though current growth is largely due to timing of revenue recognition.

Overall, DaVita's Q2 2026 results reflect a mix of positive treatment volume growth and strategic advancements in patient care, tempered by challenges in revenue per treatment and cost management. The outlook remains cautiously optimistic, with a focus on innovation and maintaining clinical standards.

DVA — DaVita Inc.